Prognostic significance of peripheral blood absolute lymphocyte count in acute lymphoblastic leukemia

doi:10.3760/cma.j.issn.1673-422X.2018.01.011

Abstract

Abstract: The prognosis of acute lymphoblastic leukemia (ALL) is affected by multiple factors. As a simple and inexpensive prognostic indicator, the peripheral blood absolute lymphocyte count (ALC) is more and more concerned. Relevant studies show that ALC values of different time points during induction therapy and its ratio show important value in the assessment of ALL prognosis, which is expected to provide a basis for subsequent individualized treatment.

Key words: Leukemia, lymphoid, Lymphocyte count, Prognosis

Li Congchi*, Hou Lihong. Prognostic significance of peripheral blood absolute lymphocyte count in acute lymphoblastic leukemia[J]. Journal of International Oncology, 2018, 45(1): 49-.

References

［1］ Ram R, Wolach O, Vidal L, et al. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediaticinspired regimens: systematic review and metaanalysis［J］. Am J Hematol, 2012, 87(5): 472478. DOI: 10.1002/ajh.23149. ［2］ Rabin KR, Gramatges MM, Borowitz MJ, et al. Absolute lymphocyte counts refine minimal residual diseasebased risk stratification in childhood acute lymphoblastic leukemia［J］. Pediatr Blood Cancer, 2012, 59(3): 468474. DOI: 10.1002/pbc.23395. ［3］ LopezLastra S, Di Santo JP. Modeling natural killer cell targeted immunotherapies［J］. Front Immunol, 2017, 8: 370. DOI: 10.3389/fimmu.2017.00370. ［4］ Preethy S, Dedeepiya VD, Senthilkumar R, et al. Natural killer cells as a promising tool to tackle cancera review of sources, methodologies, and potentials［J］. Int Rev Immunol, 2017, 36(4): 220232. DOI: 10.1080/08830185.2017.1284209. ［5］ Aerts JG, Hegmans JP. Tumorspecific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer［J］. Cancer Res, 2013, 73(8): 23812388. DOI: 10.1158/00085472.CAN123932. ［6］ Shen C, Cheng K, Miao S, et al. Latex beadbased artificial antigenpresenting cells induce tumorspecific CTL responses in the native Tcell repertoires and inhibit tumor growth［J］. Immunol Lett, 2013, 150(12): 111. DOI: 10.1016/j.imlet.2013.01.003. ［7］许秀华, 向晓星. CD4+ T细胞在肝细胞癌中的作用［J］. 国际肿瘤学杂志, 2013, 40(10): 785788. DOI: 10.3760/cma.j.issn.1673422X.2013.10.020. ［8］郑智, 方泽民, 潘友民, 等. B细胞与肿瘤免疫的研究进展［J］. 现代肿瘤医学, 2012, 20(12): 26522654. DOI: 10.3969/j.issn.16724992.2012.12.76. ［9］ Feng J, Wang Z, Guo X, et al. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large Bcell lymphoma: a metaanalysis［J］. Int J Hematol, 2012, 95(2): 143148. DOI: 10.1007/s1218501109936. ［10］ Kim Y, Kim SJ, Cheong JW, et al. Clinical impact of early recovery of peripheral blood absolute lymphocyte count after frontline autologous stem cell transplantation for diffuse large Bcell lymphoma［J］. Hematol Oncol, 2016, In press. DOI: 10.1002/hon.2332. ［11］ Suriu C, Akria L, Azoulay D, et al. Absolute lymphocyte count as a prognostic marker in newly diagnosed multiple myeloma patients［J］. Int J Lab Hematol, 2016, 38(3): e56e59. DOI: 10.1111/ijlh.12482. ［12］ Narwani V, Gabriel J, Boyd K, et al. Absolute lymphocyte count at day 29 of treatment is a powerful predictor of outcome in multiple myeloma［J］. Clin Lymphoma Myeloma Leuk, 2015, 15(4): 222226. DOI: 10.1016/j.clml.2014.10.002. ［13］ Bayraktar UD, Milton DR, Guindani M, et al. Optimal threshold and time of absolute lymphocyte count assessment for outcome prediction after bone marrow transplantation［J］. Biol Blood Marrow Transplant, 2016, 22(3): 505513. DOI: 10.1016/j.bbmt.2015.10.020. ［14］ Fungpipat P, Sophonphan J, Sosothikul D, et al. Redefining clinical risk classification in children with precursor B cell acute lymphoblastic leukemia using pretreatment absolute lymphocyte count［J］. Leuk Lymphoma, 2016, 57(4): 953956. DOI: 10.3109/10428194.2015.1081194. ［15］ Gupta A, Kapoor G, Jain S, et al. Absolute lymphocyte count recovery independently predicts outcome in childhood acute lymphoblastic leukemia: experience from a tertiary care cancer center of a developing country［J］. J Pediatr Hematol Oncol, 2015, 37(3): e143e149. DOI: 10.1097/MPH.0000000000000249. ［16］ Hirase S, Hasegawa D, Takahashi H, et al. Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia［J］. Int J Hematol, 2015, 102(5): 594601. DOI: 10.1007/s1218501518750. ［17］ Farkas T, Müller J, Erdelyi DJ, et al. Absolute lymphocyte count (ALC) after induction treatment predicts survival of pediatric patients with acute lymphoblastic leukemia［J］. Pathol Oncol Res, 2017, 23(4): 889897. DOI: 10.1007/s1225301701928. ［18］黎巧茹, 柯志勇, 谭惠珍, 等. 儿童急性淋巴细胞白血病诱导治疗结束时外周血淋巴细胞数与预后的关系［J］. 热带医学杂志, 2016, 10(16): 12671271. DOI: 16723619(2016)10126705. ［19］ Cheng Y, Luo Z, Yang S, et al. The ratio of absolute lymphocyte count at interim of therapy to absolute lymphocyte count at diagnosis predicts survival in childhood Blineage acute lymphoblastic leukemia［J］. Leuk Res, 2015, 39(2): 144150. DOI: 10.1016/j.leukres.2014.11.013. ［20］ Shen HQ, Feng JH, Tang YM, et al. Absolute lymphocyte count is associated with minimal residual disease level in childhood Bcell precursor acute lymphoblastic leukemia［J］. Leuk Res, 2013, 37(6): 671674. DOI: 10.1016/j.leukres.2013.02.002. ［21］ Rubnitz JE, Campbell P, Zhou Y, et al. Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia［J］. Cancer, 2013, 119(11): 20612066. DOI: 10.1002/cncr.28026. ［22］ Alkayed K. RE: "Lack of prognostic significance of absolute lymphocyte count after intensive induction therapy in childhood acute lymphoblastic leukemia" (PBC120049.R2)［J］. Pediatr Blood Cancer, 2014, 61(1): 184. DOI: 10.1002/pbc.24749. ［23］ Sun D, Elson P, Liedtke M, et al. Absolute lymphocyte count at day 28 independently predicts eventfree and overall survival in adults with newly diagnosed acute lymphoblastic leukemia［J］. Am J Hematol, 2012, 87(10): 957960. DOI: 10.1002/ajh.23279.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.